REGN

Regeneron Pharmaceuticals Option Alert: Jan 16 $670 Calls Sweep (5) near the Bid: 63 vs 3 OI; Earnings 5/1 Before Open [est] 

Regeneron Pharmaceuticals Option Alert: Jan 16 $670 Calls Sweep (5) near the Bid: 63 @ $100.1 vs 3 OI; Earnings 5/1 Before Open [est] Ref=$674.0

Regeneron Pharmaceuticals Stock (NASDAQ: REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

REGENERON PHARMACEUTICALS

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1100 to $1000.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1000

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 19.83% on an annualized basis producing an average annual return of 27.91%. Currently, Regeneron Pharmaceuticals has a market capitalization of $70.19 billion. 
Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based on a price of $638.70 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743177619_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Sensei Biotherapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) late Thursday released initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug (formerly SNS-101) for cancer.
The Phase 1 dose expansion trial is evaluating solnerstotug as monotherapy and in combination with Regeneron Pharmaceuticals Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Libtayo (cemiplimab) in both a basket of &#8220;hot&#8221; tumors that typically respond to immunotherapy but have progressed on prior PD-(L)1 therapy and a single &#8220;cold&#8221; tumor histology (microsatellite stable (MSS) Colorectal Cancer (CRC) that is typically <a href="https://www.benzinga.com/pressreleases/25/03/g44523662/sensei-biotherapeutics-reports-favorable-preliminary-dose-expansion-data-for-solnerstotug-in-pd-l-" target="_blank" rel="noreferrer noopener">unresponsive to immunotherapy</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44535565/penny-stock-lexicon-pharmaceuticals-surges-on-obesity-pact-worth-1-billion-with-novo-nordisk" rel="noreferrer noopener">Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk</a>
As of March 17, the study has enrolled 60 patients. Key findings include:
<ul>
<li>Among 21 evaluable PD-(L)1 resistant &#8220;hot&#8221; tumor patients, the combination of solnerstotug + cemiplimab demonstrated a 14% ORR (overall response rate), which is almost 3x higher than historical PD-(L)1 rechallenge response rates (≤5%), and a 62% DCR (disease control rate), suggesting meaningful disease <a href="https://www.benzinga.com/pressreleases/25/03/g44533399/sensei-biotherapeutics-reports-full-year-2024-financial-results-and-update-on-clinical-progress" target="_blank" rel="noreferrer noopener">control in resistant tumors</a>.</li>
<li>One durable complete response in a patient with Merkel Cell Carcinoma (MCC).</li>
<li>Two partial responses (PRs): one in a second MCC patient and one in a microsatellite instability-high (MSI-H) CRC patient.</li>
<li>All patients with tumor shrinkage remain on treatment, suggesting&nbsp;potential for prolonged clinical benefit.</li>
<li>An additional 11 patients have not yet reached the first baseline scan, and an additional eight patients discontinued the study before any post-baseline scan.</li>
<li>All patients in this cohort had progressed on prior PD-(L)1.</li>
</ul>
Six PD-(L)1 resistant patients with stable disease remain on treatment past 12+ weeks, with tumor reductions ranging from 0% to 17%, suggesting durable disease control in a subset of patients.
All PD-(L)1 resistant patients on the study with tumor shrinkage remain on treatment, suggesting&nbsp;the potential for prolonged benefit.
None of the MSS CRC patients experienced a CR or PR, consistent with prior checkpoint therapy in this &#8220;cold&#8221; tumor type.
Solnerstotug continues to be&nbsp;well tolerated, with&nbsp;no dose-limiting toxicities and the majority of AEs Grade 1 or 2 in severity.
Out of 60 patients, there have been four (7%) cases of Grade 1 cytokine release syndrome (CRS), all&nbsp;mild and manageable. Two patients in the combination cohort experienced immune-mediated events.
Price Action: SNSE stock is up 32.31% at $0.57 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44523017/ultragenyx-is-uniquely-positioned-in-long-term-remains-on-jpmorgans-focus-list" target="_blank" rel="noreferrer noopener">Ultragenyx Stays On JPMorgan&#8217;s Focus List As Analyst Highlights Strong Long-Term Positioning</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

General

SNSE

Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils
Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation

Regeneron And Sanofi's Dupixent Receives Japan's First Biologic Approval For Patients With Chronic Obstructive Pulmonary Disease (COPD)

Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock plummeted on Monday after the company released results <a href="https://www.benzinga.com/general/health-care">from its latest study</a>. 
The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment.
The study results include data from all patients through 24 weeks and most <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44454592/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-diabetic-macular-e" rel="noreferrer noopener">patients through 36 weeks</a>.
UBX1325 treatment led to visual acuity gains of over 5 letters from baseline at weeks 24 and 36 and achieved non-inferiority to Regeneraon Pharmaceuticals Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NYSE">REGN</a>) Eylea (aflibercept) at 9 out of 10-time points through 36 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44458175/ge-aerospace-opens-xeos-facility-to-power-up-leap-engine-overhauls-details" rel="noreferrer noopener">GE Aerospace Opens XEOS Facility To Power Up LEAP Engine Overhauls: Details</a>
<ul>
<li>UBX1325-treated patients had a mean change in BCVA of +5.2 ETDRS letters from baseline to 24 weeks, representing a difference of +0.4 ETDRS letters compared to the aflibercept arm.</li>
<li>UBX1325-treated patients had a mean change in BCVA of +5.5 ETDRS letters from baseline to 36 weeks, representing a difference of +0.2 ETDRS letters compared to the aflibercept arm.</li>
<li>UBX1325 was non-inferior to aflibercept at all time points through 36 weeks, except for the average of weeks 20 and 24</li>
<li>Patients on UBX1325 had an increase in Central Subfield Thickness (CST) at weeks 16 and 20, which resulted in supplemental anti-VEGF treatments in patients with significant CST gain.</li>
<li>UBX1325 generally outperformed aflibercept in patients who had moderate disease severity (baseline CST &lt; 400 microns, representing ~60% of study patients) (pre-specified analysis)</li>
<li>Patients who switched from aflibercept as their anti-VEGF treatment before study enrollment to UBX1325 had the most consistent and durable vision gains (pre-specified analysis)</li>
</ul>
UBX1325 continues to demonstrate a favorable safety and tolerability profile.
Unity anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.
As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $23.2 million, sufficient to fund operations <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44205332/unity-biotechnology-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-business-u" rel="noreferrer noopener">into the fourth quarter of 2025</a>.
Price Action: UBX stock is down 34.8% at $1.19 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44459202/alcon-eyes-surgical-edge-with-lensar-buyout-details" target="_blank" rel="noreferrer noopener">Alcon Eyes Surgical Edge With LENSAR Buyout: Details</a></li>
</ul>

Movers

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

On Monday, Opthea Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) released results from its global Phase 3 clinical trial COAST in patients with wet age-related <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">macular degeneration (wet AMD)</a>.
The trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 2 mg Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept), as per label, every eight weeks after a loading phase for wet AMD.
The trial did not meet its primary endpoint of mean change in best corrected visual acuity (BCVA) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44451744/opthea-announces-coast-phase-3-trial-topline-results" rel="noreferrer noopener">from baseline to week 52</a>.
In wet AMD patients with minimally classic and occult lesions, participants receiving sozinibercept combination therapy with a dosing regimen of every four weeks (n=296) or every eight weeks (n=297) achieved a mean change in BCVA of 13.2 or 13.2 letters from baseline to week 52, respectively, versus 13.8 letters with aflibercept monotherapy (n=299, p-values of 0.59 and 0.62 respectively).
In the overall population, participants receiving sozinibercept combination therapy with a dosing regimen of every four weeks (n=333) or every eight weeks (n=330) achieved a mean change in BCVA of 13.5 and 12.8 letters from baseline to week 52, respectively, versus 13.7 letters with aflibercept monotherapy (n=330, p-values of 0.86 and 0.42 respectively).
No numerical difference was observed in the key secondary endpoints. Sozinibercept combination therapy was well tolerated.
After the negative results from the COAST trial, Opthea is reviewing its obligations under its Development Funding Agreement (DFA) with investors.
Based on the terms of the DFA, the company may be required to make payments that could significantly impact its financial stability. Opthea could owe investors between $0 and $680 million if the agreement is terminated, depending on the circumstances.
Opthea&#8217;s leadership is actively discussing with DFA investors to explore possible solutions.
The DFA investors also hold a lien on all of Opthea&#8217;s assets, meaning the company cannot take on additional debt or sell key assets without their approval.
No decisions have been made regarding the COAST trial or whether to accelerate and unmask the ShORe trial. Discussions with DFA investors are ongoing to determine the best path forward.
As of February 28, 2025, Opthea had $113.8 million in cash and equivalents. However, there is significant uncertainty about the company&#8217;s ability to continue operating.
Opthea has requested that trading be suspended on both ASX and Nasdaq until Opthea is in a position to provide an announcement to the market by Opthea providing more clarity on these issues or the commencement of trading on March 31,&nbsp;2025.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44456336/james-hardie-acquires-building-products-maker-azek-for-875b-stock-plummets" target="_blank" rel="noreferrer noopener">James Hardie To Acquire AZEK In $8.75 Billion Deal, Expanding Its Grip On Outdoor Living Market; JHX Stock Slips</a></li>
</ul>

Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty

In the current session, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1742312723_0.png" alt="Past Year Chart" />

<h3>How Does Regeneron Pharmaceuticals P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 82.7 in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower P/E ratio of 17.69. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1742312723_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Regeneron Pharmaceuticals

WIIM

Regeneron Pharmaceuticals shares are trading lower after the Federal Circuit affirmed the denial of the company's motion in the preliminary injunction for Regeneron Pharmaceuticals V. Amgen regarding patent infringement for Eylea.

Legal

AMGN

UPDATE: Federal Circuit Affirms Denial Of Preliminary Injunction In Regeneron Pharmaceuticals V. Amgen, Upholding District Court's Finding Of No Likelihood Of Success On Patent Infringement Of U.S. Patent 11,084,865 Covering Eylea

Rumors

Watching Regeneron Pharmaceuticals, Amgen; Traders Circulate Unconfirmed Rumor That Regeneron Pharmaceuticals Court Loss Against Amgen Affirmed On Appeal, Amgen Can Continue Selling Eylea Biosimilar

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 19.54% on an annualized basis producing an average annual return of 27.57%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.92 billion. 
Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $134,486.89 today based on a price of $718.16 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741732212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

On Saturday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Kyowa Kirin Co., Ltd. <a href="https://www.benzinga.com/general/biotech">announced new results</a> from the ongoing ROCKET Phase 3 trial program rocatinlimab in moderate to severe atopic dermatitis (AD).
The IGNITE study evaluated two dose strengths of rocatinlimab and met its co-primary endpoints and all key secondary<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44208802/amgen-and-kyowa-kirin-provide-top-line-results-from-rocatinlimab-phase-3-ignite-study-in-adults-wi" rel="noreferrer noopener"> endpoints versus placebo</a>.
<ul>
<li>At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo, and 36.3% vs. 23.4% in the lower dose group.</li>
<li>In the higher dose group, 23.6% of patients achieved a validated Investigator&#8217;s Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 24, representing a 14.9% difference vs. placebo.</li>
<li>In the lower dose group, 19.1% of patients achieved this endpoint, a 10.3% difference vs. placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44159237/amgen-challenges-novo-nordisk-and-eli-lilly-as-its-monthly-weight-loss-drug-maritide-enters-two-late-stage-trials" rel="noreferrer noopener">Amgen Challenges Novo Nordisk&#8217;s Ozempic And Eli Lilly&#8217;s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials</a>
In addition, IGNITE met the endpoint of the revised Investigator&#8217;s Global (rIGA) Assessment score of 0/1 with a ≥2-point reduction from baseline.
<ul>
<li>At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4% difference vs. placebo.</li>
<li>In the lower dose group, 16.3% of patients achieved this endpoint, an 8.0% difference vs. placebo.</li>
</ul>
The ROCKET program is also informed by the results of the SHUTTLE and VOYAGER studies.
<ul>
<li>The SHUTTLE study evaluated two dose strengths of rocatinlimab in combination with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI) in 746 adults using the same co-primary endpoints as IGNITE. The study met its co-primary and all key secondary endpoints.
<ul>
<li>For EASI-75, 52.3% of patients in SHUTTLE&#8217;s higher dose group achieved the endpoint, a 28.7% difference vs. placebo, while 54.1% of patients in the lower dose group achieved the endpoint, a 30.4% difference vs. placebo.</li>
<li>For vIGA-AD 0/1, 26.1% of SHUTTLE patients in the higher dose group achieved the endpoint, a 13.8% difference vs. placebo. In the lower dose group: 25.8% vs. 13.5%.</li>
<li>For rIGA 0/1, 23.3% of SHUTTLE patients in the higher dose group achieved the endpoint, an 11.5% difference vs. placebo and 22.7% vs. 10.9% in the lower dose group.</li>
</ul>
</li>
</ul>
The VOYAGER study demonstrated that rocatinlimab does not interfere with responses to tetanus and meningococcal vaccinations.
William Blair writes rocatinlimab results validate the OX40 mechanism, likely supporting a moderate commercial opportunity for patients after Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent and Eli Lilly &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Ebglyss.
Price Action: AMGN stock is up 2.4% at $332.90 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44223752/india-based-sun-pharma-to-buy-us-cancer-firm-checkpoint-therapeutics-for-410-per-share" target="_blank" rel="noreferrer noopener">India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details</a></li>
</ul>
Photo: Shutterstock

Large Cap

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

On Friday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) released new results from Ebglyss&#8217;s (lebrikizumab-lbkz) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">long-term study, ADjoin</a>.
New data shows Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44189249/lillys-ebglyss-lebrikizumab-lbkz-single-monthly-maintenance-injection-achieved-completely-clear-sk" rel="noreferrer noopener">at three years</a>.
Ebglyss was approved in the U.S. in&nbsp;September 2024&nbsp;as a first-line monotherapy biologic treatment option following <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss" rel="noreferrer noopener">topical prescription therapies</a>.
Of the patients who responded to treatment at Week 16 and received once-monthly maintenance dosing, 50% achieved complete skin clearance (EASI 100 or IGA 0) at three years.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
Additionally, 87% achieved or maintained almost-clear skin (EASI 90) at three years.
Over 83% of Week 16 responders taking EBGLYSS did not require concomitant therapies such as topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) for the duration of the ADjoin study.
Additional study assessments conducted in patients with skin of color (<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4376941-1&amp;h=4271923845&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2024-03-10-More-than-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-experienced-skin-improvement-in-a-first-of-its-kind-lebrikizumab-study&amp;a=ADmirable" rel="noreferrer noopener">ADmirable</a>) and patients who were previously treated with Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) / Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) (<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4376941-1&amp;h=695585820&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2024-10-25-Lillys-EBGLYSS-TM-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-relief-in-the-majority-of-patients-with-moderate-to-severe-atopic-dermatitis-who-discontinued-dupilumab&amp;a=ADapt" rel="noreferrer noopener">ADapt</a>) showed improvements in itch, skin pain (discomfort and soreness), and itch interference with sleep.
<ul>
<li>In ADmirable, nearly 60% of patients achieved significant improvement in itch and skin pain at Week 16 (58% and 59%, respectively). Over 30% of patients saw a reduction in sleep loss due to itch at Week 16.</li>
<li>In ADapt, 75% achieved significant improvement in skin pain, and 62% achieved significant improvement in itch at Week 24. 42% of patients saw a reduction in sleep loss <a href="https://www.benzinga.com/general/biotech/24/10/41553086/eli-lillys-newly-fda-approved-eczema-drug-improves-skin-and-itch-in-patients-previously-treated-w" target="_blank" rel="noreferrer noopener">due to itch at Week 24</a>.</li>
</ul>
Price Action: LLY stock is down 0.36% at $909.50 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/03/44189581/saas-company-liveramp-lays-off-5-of-full-time-workforce-amid-strategic-restructuring" target="_blank" rel="noreferrer noopener">SaaS Company LiveRamp Lays Off 5% Of Full-Time Workforce Amid Strategic Restructuring</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients

On Monday, Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) released interim Phase 1 results from its first-in-human <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44071970/apogee-therapeutics-announces-positive-interim-phase-1-results-from-the-apg990-healthy-volunteer-t" rel="noreferrer noopener">trial of APG990</a>.
APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of approximately 60 days across doses tested.
Key data from the 40-healthy subject trial showed:
<ul>
<li>APG990 demonstrated a potential best-in-class PK profile, including a half-life of approximately 60 days, supporting the potential for every three- and six-month maintenance dosing. The PK profile supports the potential for a single 2 mL co-formulated injection of APG279 (APG777 + APG990) administered every three and six months.</li>
<li>APG990 was well tolerated across all five cohorts, with doses up to 1,200mg. The most common (≥10%) treatment-emergent adverse events (TEAEs) were headache.53% of participants observed at least one TEAE.</li>
<li>There were no Grade 3 TEAEs related to the study drug or severe adverse events. No adverse events led to study discontinuation. There have been no cases of pyrexia or chills.</li>
</ul>
In addition, preclinical studies of the combination of APG777 and APG990 showed potential for enhanced pharmacologic responses relative to individual agents and exhibited no safety findings at any dose level, including the highest dose tested of 150 mg/kg per agent in a 3-month combination toxicology study.
The company plans to submit an Investigational New Drug application or foreign equivalent for APG279.
Following clearance, the company plans to initiate a Phase 1b clinical trial in moderate-to-severe atopic dermatitis (AD) of APG279 against Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) / Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) in 2025, with data expected in the second half of 2026.
The company says cash, cash equivalents, and marketable securities were $731.1 million as of December 31, 2024. Based on current operating plans, Apogee expects its existing cash, cash equivalents, and marketable securities will enable the company to fund its operating expenses into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44072186/apogee-therapeutics-provides-pipeline-progress-and-reports-full-year-2024-financial-results" rel="noreferrer noopener">first quarter of 2028</a>.
Price Action: APGE stock is up 7.14% at $33.68 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44072910/ast-spacemobile-teams-up-with-vodafone-for-satellite-broadband-service-across-europe" target="_blank" rel="noreferrer noopener">AST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe</a></li>
</ul>

APGE

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Regeneron Says EMA CHMP Adopted Positive Opinion Recommending Conditional Marketing Authorization Of Linvoseltamab To Treat Adults With Relapsed And Refractory Multiple Myeloma

Regeneron Says EMA's CHMP Adopted Positive Opinion Recommending Conditional Marketing Authorization Of Linvoseltamab In Relapsed/Refractory Multiple Myeloma

FDA Accepts Odronextamab BLA For Review In R/R Follicular Lymphoma, Decision Expected By July 30, 2025

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in REGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Regeneron Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $104,155, and 14 are calls, amounting to $721,715.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $460.0 to $1000.0 for Regeneron Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 49.46, with a total volume reaching 223.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $460.0 to $1000.0, throughout the last 30 days.
<h3>Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740510946_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$295.0</td>
<td>$290.0</td>
<td>$295.0</td>
<td>$460.00</td>
<td>$147.5K</td>
<td align="right">15</td>
<td align="right">0</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.8</td>
<td>$53.0</td>
<td>$53.0</td>
<td>$750.00</td>
<td>$79.5K</td>
<td align="right">127</td>
<td align="right">21</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$79.0</td>
<td>$76.0</td>
<td>$79.0</td>
<td>$950.00</td>
<td>$71.1K</td>
<td align="right">21</td>
<td align="right">9</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$143.7</td>
<td>$135.4</td>
<td>$140.51</td>
<td>$850.00</td>
<td>$70.2K</td>
<td align="right">51</td>
<td align="right">5</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$131.0</td>
<td>$123.0</td>
<td>$126.83</td>
<td>$700.00</td>
<td>$63.4K</td>
<td align="right">46</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Regeneron Pharmaceuticals</h3>
<ul>
<li>With a trading volume of 578,077, the price of REGN is up by 1.55%, reaching $724.34.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $839.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $1013. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Regeneron Pharmaceuticals, which currently sits at a price target of $759. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Regeneron Pharmaceuticals, targeting a price of $750. 
&#x2A; In a positive move, an analyst from Leerink Partners has upgraded their rating to Outperform and adjusted the price target to $834. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Regeneron Pharmaceuticals Unusual Options Activity For February 25

On Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the <a href="https://www.benzinga.com/pressreleases/25/02/g43923628/latest-db-oto-results-demonstrate-clinically-meaningful-hearing-improvements-in-nearly-all-childre" target="_blank" rel="noreferrer noopener">otoferlin (OTOF) gene</a>.
Regeneron snapped up DB-OTO through its&nbsp;$109 million acquisition&nbsp;of Decibel Therapeutics <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33664344/decibel-therapeutics-stock-soars-on-acquisition-deal-the-details" rel="noreferrer noopener">in August 2023</a>.
Congenital deafness (hearing loss present at birth) affects approximately 1.7 out of every 1,000 children born in the U.S. Approximately half of these cases have genetic causes.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43470883/regenerons-q4-earnings-surpass-estimates-launches-quarterly-dividend-and-additional-stock-buyback-program" rel="noreferrer noopener">Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program</a>
However, otoferlin-related hearing loss is ultra-rare. It is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein critical for communication between the inner ear&#8217;s sensory cells and the auditory nerve.
These include 72-week results showing speech and development progress in the first child dosed at 10 months of age and initial results in 11 children (aged 10 months to 16 years old) – three of whom received DB-OTO bilaterally (in both ears).
Among the 11 participants with at least one post-treatment assessment, 10 demonstrated a notable response, with improved hearing at various decibel hearing levels. Additionally, among five participants with 24-week assessments, three experienced improvements in average hearing thresholds to &#8220;nearly normal&#8221; or normal hearing levels.
One participant did not experience a change from their baseline hearing at 24 weeks post-dosing.
Across all 12 participants, the surgical procedure and DB-OTO were well tolerated and no adverse or serious adverse events were considered related to DB-OTO.
Five of the 12 participants experienced transient post-surgical vestibular adverse events (e.g., nystagmus, nausea, dizziness, vomiting), which resolved within 6 days of dosing.
Price Action: REGN stock closed at $713.25 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43910591/fresh-del-monte-stock-falls-as-q4-sales-earnings-miss-expectations" target="_blank" rel="noreferrer noopener">Fresh Del Monte Stock Falls As Q4 Sales &amp; Earnings Miss Expectations</a></li>
</ul>
Photo: Shutterstock

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing
Speech and development progress followed dramatic improvements in hearing in first child treated in the trial
TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene. These include 72-week results showing speech and development progress in the first child dosed at 10 months of age, as well as initial results in 11 children (aged 10 months to 16 years old) – three of whom received DB-OTO bilaterally (in both ears). The latest results were presented in an oral presentation at the Association for Research in Otolaryngology's (ARO) 48th Annual MidWinter Meeting.

Regeneron Pharmaceuticals Presents Latest DB-OTO Results, Says Demonstrate Clinically Meaningful Hearing Improvements In Nearly All Children With Profound Genetic Hearing Loss In CHORD Trial; As Presented At ARO, 10 Of 11 Children With At Least One Post-Treatment Assessment Showed Notable Improvements In Hearing

Press Releases

Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation

Earnings

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

ALNY

COEP

PARIS:SAN

RPRX

SMMT

VRTX

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Regeneron Pharmaceuticals

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL